Gilead Sciencesvs.United Therapeutics
GILD vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 7.6× larger than United Therapeutics by market cap; year to date, Gilead Sciences leads (+19.6% vs +5.3%).
Side by side
| GILD | UTHR | |
|---|---|---|
| Market cap | $170B | $22.3B |
| Price | $148.77 | $518.53 |
| Today | +1.4% | +1.1% |
| Return YTD | +19.6% | +5.3% |
| Return 1Y | +27.9% | +64.3% |
| P/E | — | 17.0 |
| P/S | 5.6 | 7.1 |
| P/B | 14.4 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More GILD & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and UTHR sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →